ARCHIVES

Recurrent Multiple Myeloma Responds To Revimid In Phase II, Side Effects Tolerable

This article is from The Cancer Letter archive.

Vol. 26 No. 1 | January 31, 2003

Download PDF Visit The Full Archive

Related Articles

CALG Loses Pediatrics Grant

July 20, 1979

Gene Expression Test Accurately Classifies “Inconclusive” Samples

July 27, 2012

NIH Faces Cuts Under House, Senate, Administration Plans

May 19, 1995

FDA Simplifies Reporting Of Adverse Events

June 18, 1993

In Brief: President OK’s Mammography Standard Publication, CDC State Grants Increase

January 7, 1994

In Brief: D. Gary Gilliland Named President and Director of Fred Hutchinson Cancer Research Center

November 21, 2014